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All known heme-thiolate proteins ligate the heme iron using
one cysteine side chain. We previously found that DiGeorge
Critical Region 8 (DGCR8), an essential microRNA processing
factor, associates with heme of unknown redox state when over-
expressed inEscherichia coli. On the basis of the similarity of the
450-nm Soret absorption peak of the DGCR8-heme complex to
that of cytochrome P450 containing ferrous heme with CO
bound, we identified cysteine 352 as a probable axial ligand in
DGCR8. Here we further characterize the DGCR8-heme inter-
action using biochemical and spectroscopic methods. The
DGCR8-heme complex is highly stable, with a half-life exceed-
ing 4 days. Mutation of the conserved proline 351 to an alanine
increases the rate of heme dissociation and allows the DGCR8-
heme complex to be reconstituted biochemically. Surprisingly,
DGCR8 binds ferric heme without CO to generate a hyperpor-
phyrin spectrum. The electronic absorption, magnetic circular
dichroism, and electron paramagnetic resonance spectra of the
DGCR8-heme complex suggest a ferric heme bearing two cys-
teine ligands. This model was further confirmed using seleno-
methionine-substituted DGCR8 andmercury titration. DGCR8
is the first example of a heme-binding protein with two endog-
enous cysteine side chains serving as axial ligands. We further
show that native DGCR8 binds hemewhen expressed in eukary-
otic cells. This study provides a chemical basis for understand-
ing the function of the DGCR8-heme interaction in microRNA
maturation.
Heme proteins use a variety of amino acids to serve as the
axial ligands (the fifth and possibly sixth ligands) for the heme
iron. In many cases, such as with hemoglobins (1), soluble gua-
nylate cyclases (2) and heme oxygenases (3), an imidazole moi-
ety of a histidine side chain acts as the fifth ligand. Another
major class of heme-binding proteins, exemplified by the cyto-
chrome P450 proteins (4), chloroperoxidases (5), and nitric
oxide synthases (6), uses a cysteine side chain as the fifth ligand.
This class is called heme-thiolate proteins (7). The functions of
these axial ligands include enhancing the affinity and specificity
of the protein-heme interaction, modulating the redox proper-
ties of the heme, and enabling the heme to serve as catalysts,
transporters, or sensors (8, 9). Often, the sixth ligand of the iron
in heme is a substrate, a cargo, or a protein moiety that modu-
lates the biological activities of the protein.
We have previously found that the RNA-binding partner
protein of the Drosha nuclease in humans, called DiGeorge
Critical Region 8 (DGCR8)3 (or Pasha for its insect and worm
homologs), is a heme-binding protein (10). DGCR8 (11–14)
and Drosha (15) are responsible for processing primary tran-
scripts of microRNAs (pri-miRNAs) into precursor miRNAs in
the first step of the miRNA maturation pathway in animals
(16–18). A truncated but active form of DGCR8 named NC1,
containing residues 276–751 of this 773-amino acid protein
(Fig. 1A), exists as a heme-bound dimer and heme-free mono-
mer when overexpressed in Escherichia coli (10). The heme-
bound NC1 dimer is more active in reconstituted pri-miRNA
processing assays than the heme-freemonomer, indicating that
heme is important for the function of DGCR8. Heme-binding-
deficient NC1 mutants are defective in pri-miRNA processing
in vitro (10, 19). DGCR8 binds heme through a heme-binding
domain (HBD, amino acids 276–498) that can be expressed in
a soluble, heme-bound form in the absence of other domains
(Fig. 1A) (19). The HBD is not required for binding and pro-
cessing pri-miRNAs in vitro and most likely serves a regulatory
function (10). The N-terminal region of the HBD (amino acids
276–353) is a dimerization subdomain that includes a WW
motif, which is most often involved in binding proteins with
proline-containing sequences (19). The crystal structure of this
domain, in the absence of heme, revealed a novel use of itsWW
motif for dimerization (19). Importantly, the structure showed
that all the residues known to be essential for association with
heme, including Cys-352 and Trp-329 (the second W in the
WW motif) from both subunits, cluster on a common surface
that presumably directly contacts heme.
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DGCR8 appears to belong to a previously uncharacterized
family of heme proteins. Heme-bound NC1 exhibits electronic
absorption peaks at 450, 367, and 556 nm, with the 367-nm
peak almost as intense as the strongest 450-nm peak. The Soret
peak at 450 nm is characteristic for heme-binding proteins
with a thiolate ligand contributed by a cysteine side chain (20,
21). The Soret peak of the heme-thiolate protein cytochrome
P450 red-shifts to450nmwhen the iron in heme is reduced to
the ferrous state and CO binds as the sixth ligand (22). Consis-
tent with this precedent, mutation of a conserved Cys-352 to
alanine, serine, or histidine in NC1 abolishes heme binding,
implying that Cys-352 is an axial ligand of the iron in the heme
(10). However, there is no obvious source of CO in the purifi-
cation and storage of recombinant NC1. Furthermore, in cyto-
chrome P450, ferrous heme ligated by a cysteine thiolate trans
to CO exhibits a spectrum with the 366-nm band substantially
less intense than the 450-nm peak. Our understanding of the
DGCR8-heme interaction has been limited by a lack of in vitro
heme-binding assays, as incubation of the heme-free monomer
with heme does not produce the heme-bound dimer. In addi-
tion, there does not appear to be any interchange between the
dimer and monomer species in vitro, regardless whether heme
is present.
In this study, we used a diverse set ofmethods to examine the
redox and ligation states of the heme in DGCR8. A mutant
NC1, P351A, was shown to reversibly bind heme, forming a
reconstituted complex that displays an electronic absorption
spectrum similar to that of the wild-type protein. Heme disso-
ciation and association assays revealed heretofore unknown
properties of DGCR8.Most notably, DGCR8 stably binds ferric
heme and exhibits the 450-nm Soret peak in the absence of CO.
Spectroscopic characterization of the DGCR8 HBD reveals
unique features associated with the uncommon heme coordi-
nation environment, including a narrow g anisotropy in the
EPR spectrum. These results, along with SeMet substitution
and mercury titration experiments, demonstrate that DGCR8
is a novel heme-binding proteinwith two cysteine side chains as
axial ligands. Additionally, we show that DGCR8 binds heme
when expressed in eukaryotic cells. The unique interaction
between DGCR8 and heme provides the biochemical basis for
understanding a potential mechanism for regulating miRNA
maturation.
EXPERIMENTAL PROCEDURES
Reagents—Horse skeletal muscle apomyoglobin was from
Sigma-Aldrich (St. Louis, MO). Hemin and -ALA were from
MP Biomedicals (Solon, OH). L-()-selenomethionine was
from Acros Organics (Morris Plains, NJ). Methylmercury(II)
acetate (MeHgAc) was purchased as a part of a heavy atom
screening kit from Hampton Research (Aliso Viejo, CA). Cau-
tion: MeHgAc is extremely toxic and should be handled with
great care.
Plasmids—Site-directed mutagenesis of NC1 and human
DGCR8 HBD-His6 in the pET-24a vector was carried out
using the standard four-primer PCR method (19). The insect
cell expression plasmid for His6-NC1 was generated by cloning
the coding sequence for residues 276–751 of human DGCR8
into the pFastBac-HTb vector between the BamHI and EcoRI
sites. The cDNA clone of the DGCR8 homolog from Xenopus
laevis (frog) was obtained from Open Biosystems. The HBD
coding region of the frog DGCR8 (amino acids 278–498) was
amplified using PCR and was inserted into the pET-24a vec-
tor between the NdeI and NotI sites. The coding sequences of
all plasmids were verified through sequencing.
Protein Expression and Purification—NC1 constructs were
expressed and purified as described previously (10). The heme-
bound proteins were expressed with 1 mM -ALA added at
induction. The purification procedure started with two rounds
of ion exchange chromatography using a SP-Sepharose HP col-
umn, and themonomer and dimer specieswere separated using
size exclusion chromatography (SEC) and a Superdex 200
10/300 GL column (GE Healthcare).
The frog DGCR8 HBD-His6 was expressed in E. coli strain
BL21(DE3) CodonPlus (Strategene) and purified using Ni-af-
finity chromatography followed by SEC, as reported previously
for humanHBD-His6 (19). The purified protein was exchanged
into desired buffers for spectroscopic studies, as indicated in
the figure legends, using centrifugal concentrators with a
molecular mass cut-off of 30 kDa. SeMet-labeled frog DGCR8
HBD-His6was expressed using the same vector, host strain, and
procedure as described by Van Duyne et al. (23). Briefly, E. coli
were cultured in M9 minimal medium containing no methio-
nine. Six other amino acids known to inhibit methionine bio-
synthesis were added to the culture 15 min prior to induction.
In addition, 40 M FeCl3 and 1 mM -ALA were added to the
medium at induction to increase the synthesis of heme and the
yield of the HBD-heme complex. SeMet-labeledHBD-His6 was
expressed at 25 °C overnight (16 h) and purified using the
same procedure as that for the unlabeled protein.
The human DGCR8 HBD-His6 C430S mutant protein
(hHBDC430S, used in a mercury titration experiment) was
expressed and purified using the same procedure as described
for the wild-type protein (19), except that the SEC was per-
formed in the absence of reducing reagents. Prior to the mer-
cury titration experiments, the purified HBD mutant was con-
centrated and exchanged into a buffer containing 50 mM EPPS
(pH 8.0) and 400 mM NaCl, using a centrifugal concentrator
with a molecular mass cut-off of 30 kDa. The extinction coeffi-
cient of the heme-bound hHBDC430S protein (280 nm  31
mM1 cm1) was determined experimentally by measuring its
absorption at 280 nm and its protein concentration using the
Micro BCA protein assay kit (Pierce).
The His6-NC1 protein was expressed in Sf9 cells following
the instructions in the Bac-to-Bac system (Invitrogen). His6-
NC1 was purified using Ni-affinity chromatography followed
by cation exchange chromatography using a SP column (GE
Healthcare). The purified protein fractions were pooled, con-
centrated, and exchanged in a storage buffer containing 20 mM
Tris (pH 8.0), 400 mM NaCl, and 1 mM DTT using an Ultra-4
concentrator with a 30-kDa molecular mass cut-off. Sf9 cell-
expressedHis6-NC1was analyzed using a Superdex 200 10/300
GL column, and the absorption at 260, 280, and 450 nm was
monitored (Fig. 9B). The size exclusion chromatogram was
baseline-adjusted using the Unicorn software (version 5.0, GE
Healthcare). The ratio of the absorption by heme andby protein
(theRZ value)was used to calculate the percentage ofHis6-NC1
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occupied by heme using the extinction coefficients () 58mM1
cm1 for heme (450 nm) and 53mM1 cm1 for eachHis6-NC1
subunit (280 nm). The 450 nm of insect cell-expressed His6-
NC1 was assumed to be the same as that of the untagged NC1
expressed in E. coli (10). The 280 nm was calculated from the
His6-NC1 sequence using the program ProtParam on the
ExPASy proteomics server provided by the Swiss Institute of
Bioinformatics (24).
Heme Dissociation and Association Assays—Hemin chloride
was dissolved in 1.4 M NaOH at 100 mM concentration and
incubated at room temperature for 30 min. This concen-
trated solution was then diluted in water to give a 100 M stock
solution. All reactions were carried out in 20 mM Tris buffer
(pH 8.0), 400 mM NaCl, and 1 mM DTT, unless otherwise
specified.
Electronic Absorption Spectroscopy—The spectra were re-
corded at 25 °C using either a DU800 spectrophotometer
(Beckman-Coulter, bandwidth  1.8 nm) in sealed cuvettes
(Figs. 1–4, 8, 9), a DU500 spectrophotometer (Beckman-
Coulter, bandwidth 4.5 nm) (Fig. 3D), or a double-beamVar-
ian Cary 4 Bio spectrophotometer (Agilent Technologies) with
its spectral bandwidth set to 0.5 nm (Figs. 5 and 7B).
MCD Spectroscopy—MCD spectra were recorded on a Jasco
J-715 circular dichroism spectropolarimeter with the sample
compartment modified to accommodate an SM-4000–8T
magnetocryostat (Oxford Instruments). The buffer used for the
MCD samples was 50mMEPPS and 400mMNaCl (pH 8.0) with
55% (v/v) glycerol present in the final sample. Glycerol was
introduced to the protein and stirred with a syringe until the
solution was homogenous. Glycerol had no effect on the elec-
tronic absorption spectra at room or liquid-helium tempera-
tures. Samples were transferred via gas-tight syringes into cells,
flash-frozen, and stored in liquid N2. MCD spectra were taken
over a temperature range from 4 to 50 K. The MCD signal at
each temperature was recorded at 7 T. Negative polarity
data were subtracted from positive polarity data to remove
circular dichroism contributions, and the resulting spec-
trum was divided by 2. Magnetic saturation curves were gen-
erated from data taken at 448 nm, and data were normalized
to the most intense MCD data point (7 T, 2.5 K).
EPR Spectroscopy—X-band electron paramagnetic reso-
nance spectra were collected on a Bruker ELEXSYS E500
equipped with an Oxford ESR 900 continuous flow liquid
helium cryostat and an Oxford ITC4 temperature controller
maintained at 10 K. The microwave frequency was monitored
using an EIP model 625A CW microwave frequency counter.
Protein samples were prepared as indicated in the figure leg-
ends. Samples were transferred to a quartz EPR tube via small-
bore tubing connected to a gas-tight syringe and were frozen in
liquid N2. Samples of 150 l had a final concentration of 150
M heme. For all samples, scans of 0–10,000 G revealed no
signals other than those reported.
MALDI-TOFMass Spectrometry—Native and SeMet-labeled
frog DGCR8HBD-His6 were dissolved in a 1:9 (v/v) ratio with a
mixture containing 70% (v/v) acetonitrile, 0.1% (v/v) trifluoro-
acetic acid, and saturating concentration of sinapinic acid
(Fluka). The samples were analyzed using a Voyager-DE STR
MALDI-TOF mass spectrometer (Applied Biosystems) oper-
ated in a linear mode with positive polarity. The mass accuracy
in this mode is   0.05% for myoglobin (16,952 Da). Them/z
range from 10,000 to 70,000 was monitored.
Mercury Titration of Cysteines in Human HBD—A stock
solution ofMeHgAcwas prepared at a 0.5mM concentration in
50 mM EPPS (pH 8.0) and 400 mM NaCl. (Caution: MeHgAc is
volatile and extremely toxic. The stock solutionwas prepared in
a fume hood.) TheMeHgAc stockwas added to 200l of 10-M
hHBDC430S dimer solution in 2-l increments. The solution
was incubated at 25 °C for 10 min before the electronic absorp-
tion spectra were recorded. After themercury titration, 30l of
apomyoglobin stock solution (80 M) was added, and the elec-
tronic absorption spectrum was recorded.
Reconstituted pri-miRNA Processing Assays—The procedure
was described previously (10). Briefly, the 150-nucleotide pri-
miR-30a was uniformly labeled with 32P and was incubated
with recombinant Drosha and His6-NC1 at 37 °C for 45 min.
The reactions were analyzed using denaturing 15% polyacryl-
amide gels and autoradiography.
RESULTS
The DGCR8 P351A Mutant Can Be Expressed as Heme-
bound and Heme-free Dimers—Pro-351 is located close to the
proposed heme-binding surface of DGCR8 in three-dimen-
sional space (19).Wemutated Pro-351 to alanine in the context
of NC1 (P351A) and examined the ability of thismutant to bind
heme by expressing it in E. coliwith andwithout the addition of
-ALA, a heme biosynthesis intermediate. In both cases, P351A
was present in dimeric and monomeric forms, as indicated by
SEC (Fig. 1, B and C). When overexpressed without -ALA,
P351A was nearly completely free of heme (Fig. 1B). When
-ALA was added to the bacterial culture at the time of induc-
tion, the heme occupancy of the P351A dimer was increased to
nearly the level of the wild type under the same conditions;
however, the P351Amonomer remained free of heme (Fig. 1C).
The heme-bound P351A dimer, purified using SEC, exhibited
an electronic absorption spectrum with peaks at 365, 447, and
556 nm, similar to those of the wild-type NC1 protein (Fig. 1C).
The P351A mutation caused a 3-nm blue shift of the 450-nm
Soret peak, indicating some alteration in the local structure of
the NC1 protein. In the presence of -ALA, the wild-type NC1
is expressed nearly exclusively as a heme-bound dimer (10),
suggesting that the P351A mutation may reduce the affinity of
DGCR8 for heme. Overall, these results suggest that the com-
plex of P351A with heme retains a structure similar to that of
the wild type.
Heme Dissociates from Wild-type DGCR8 Extremely Slowly,
and the P351A Mutation Increases the Dissociation Rate—To
determine the stability of the DGCR8-heme complex, we per-
formed a heme dissociation assay by incubating heme-bound
NC1 with 5-fold molar excess of horse apomyoglobin. Apo-
myoglobin has an extremely high affinity for heme, with KD of
3  1015 M (25). Thus, heme molecules dissociated from
NC1 were quickly bound to apomyoglobin, and this transfer
was accompanied by a shift of the Soret peak from 450 to 414
nm (Fig. 2A). At room temperature, heme dissociated from the
P351A dimer within 1–2 h (Fig. 2A). When the absorbance at
447 nmwas plotted over time, the data fit nicely to a one-phase
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exponential decay function, giving an estimated dissociation
rate constant (koff) of 5.0  0.1  104 s1. The increase in
absorbance at 414 nm over time gave a similar value (5.8 
0.4  104 s1). In contrast, incubation of wild-type heme-
boundNC1with apomyoglobin did not result in any shift of the
Soret peak even after 4 days (Fig. 2C). This observation suggests
either extremely slow dissociation of heme from the wild-type
NC1 (with t1/2  4 days or koff  3  106 s1) or a higher
affinity of wild-type NC1 for heme than that of apomyoglobin.
By comparison, the koff for sperm whale myoglobin is 8.4 
107 s1, that for human hemoglobin is 7.1 106 s1 (26, 27),
and the koff for the single-cysteine-ligated heme-sensor pro-
teins such as heme-regulated inhibitor and neuronal PAS pro-
tein 2 (NPAS2) are typically 1–6  103 s1 (21). The heme-
sensor proteins are a group of heme-binding proteins in which
the activity is regulated either directly by heme or by signaling
gas molecules such as NO and CO. The slow dissociation of
heme from NC1 argues against a model in which activity of
DGCR8 is reversibly regulated by its association with heme.
Furthermore, the P351A mutation increases the dissociation
rate of the heme from NC1, possibly by altering the conforma-
tion of the loop containing Cys-352.
The P351A-Heme Complex Can Be Reconstituted Using Fer-
ric Heme—It has not been possible to reconstitute the DGCR8-
heme complex by incubating hemewith theNC1monomer, the
only heme-free form of the wild-type protein currently avail-
able.Wewonderedwhether the heme-free P351A dimer would
bind heme in vitro. We titrated ferric heme into the heme-free
P351A dimer and found that they readily formed a specific
complex. The P351A-heme complex displayed absorption
peaks at 365, 447, and 556 nm (Fig. 3A), nearly identical in
positions and relative intensities to those of the heme-bound
P351A dimer purified from E. coli. As the total ferric heme con-
centration increased, the 447-nm and 556-nm absorption pla-
teaued after4.5M (Fig. 3,A andB), close to the P351A dimer
concentration of 4.35 M. This result suggests that each P351A
dimer binds one ferric hememolecule. The same protein-heme
stoichiometry was previously observed for the wild-type NC1
dimer when it was characterized using HPLC and mass spec-
trometry (10). In contrast, the absorbance at 365 nm continued
to increase linearly after the specific heme-binding site of
P351A had been saturated (Fig. 3B). Both specific and nonspe-
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cific NC1-heme interactions appear to contribute to the
365-nm peak (see below). The reconstituted P351A dimer-fer-
ric heme complex was analyzed using SEC. The absorbances at
280, 370 and 450 nm coeluted in a peak with an elution volume
similar to those of the heme-bound and heme-free P351A
dimers, indicating that the complex was stable and remained as
a dimer (Fig. 3C). In contrast to the dimer, the heme-free P351A
monomer is incapable of binding ferric heme. Incubation of the
heme-free P351A monomer with ferric heme yielded an
absorption peak at 372 nm and no Soret peak at 450 nm (Fig.
3D), indicative of nonspecific heme binding. SEC of the heme-
free P351A monomer incubated with ferric heme showed that
the protein did not coelute with heme (supplemental Fig. S1).
Thus, the heme-free P351A monomer cannot bind heme and
convert to the heme-bound dimer under the conditions tested.
These results confirm the previous finding that dimerization of
DGCR8 is required for associationwith heme (10). Importantly,
the in vitro heme-binding assays of the P351A dimer were per-
formed in the absence of CO (Fig. 3A). The fact that DGCR8
binds ferric heme without CO to give a Soret peak at 450 nm
clearly demonstrates that it must bind heme through a set of
interactions distinct from those in ferrous cytochrome P450
bound by CO.
The Hyperporphyrin Spectrum of DGCR8 Matches Those of
Ferric Heme with Two Thiolate Ligands—How does DGCR8
interact with ferric heme to generate the 450-nm absorption
peak? The similarly intense absorption peaks at 450 nm and
366 nm in the DGCR8-heme complexes constitute a hyper-
porphyrin (split Soret) spectrum. Early studies showed that
having a ferrous heme ligated with a cysteine (thiolate) and CO
is not the only way to obtain a hyperporphyrin spectrum. Ferric
heme in complex with two mercaptide ligands, used as model
compounds for hemoproteins, can produce a hyperporphyrin
spectrum with the split Soret bands of approximately equal
intensity (28). Similarly, ligation of an exogenous thiolate or
phosphine compound to ferric heme-thiolate proteins, such as
cytochrome P450CAM and chloroperoxidase, also generates
hyperporphyrin spectra with two equally intense Soret bands
(supplemental Table S1) (29–31). The electronic absorption
spectrum of the NC1-heme complex bears a striking similarity
to that of chloroperoxidase with an exogenous thiolate ligand
(Fig. 4). Additionally, these studies on cytochrome P450CAM
and chloroperoxidase showed a broad / band with its maxi-
mum at 560 nm, similar to the 556-nm peak in the electronic
absorption spectrum of the NC1-heme complex (29–31). The
match of these electronic absorption spectroscopic signatures
suggests that DGCR8 likely binds ferric heme using a cysteine
thiolate as the fifth ligand and a sixth ligand that could be either
a thiolate or a phosphine. Unlike cytochrome P450 and chlo-
roperoxidase, DGCR8 (both NC1 and HBD-His6) can be puri-
fied and stored in the absence of any exogenous thiolate- or
phosphine-containing compounds and still maintain its hyper-
porphyrin spectrum, suggesting that DGCR8mostly likely uses
two endogenous ligands. These ligands could be the side chain
of a cysteine (thiolate or thiol) or a methionine (an electron
donor similar to the phosphine).
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MCD and EPR Spectra Reveal Spin, Oxidation, and Coordi-
nation States of theHeme inDGCR8—WeperformedMCDand
EPR spectroscopies to further interrogate the chemical envi-
ronment of the heme in DGCR8. Because these techniques
require large amounts of protein, we chose to use the C-termi-
nal His6-tagged heme-binding domain (HBD-His6) from frog
DGCR8 (Fig. 1A), which can be expressed and purified with a
yield of1mgper liter of bacterial culture. TheHBDsequences
of human and frog DGCR8 are 80% identical. The electronic
absorption spectrum of the frog DGCR8 HBD-His6 (Fig. 5,
upper panel) is nearly identical to those of the human DGCR8
NC1 and HBD-His6 (19) proteins, indicating a close similarity
between the chemical environments of their heme cofactors.
The MCD spectrum of the frog DGCR8 HBD-His6 protein,
recorded at 4 K, is dominated by two features with peak-cross-
over-trough positions of 344-368-388 nmand 430-435-448 nm,
respectively (Fig. 5, lower panel). These features correspond to
the blue-shifted and red-shifted split Soret bands in the absorp-
tion spectrum.Weaker features are observed in theMCD spec-
trum between 500 and 750 nm that correspond to the / (557
nm) and ligand-to-metal charge-transfer transition (660 nm)
peaks in the absorption spectrum. The MCD spectrum of the
frog HBD-His6 bears the greatest resemblance toMCD spectra
of ferric chloroperoxidase and ferric P450CAM to which either
methanethiol or bis(hydroxymethyl)methylphosphine has
been added (5, 31, 32), further supporting the model in which
the heme iron in DGCR8 is six-coordinate with one cysteine
thiolate ligand, and a sixth ligand that may be either another
cysteine (equivalent to themethanethiol) or amethionine (sim-
ilar to the phosphine). To probe the electronic state of themetal
iron, MCD spectra of the frog HBD-His6 were recorded over a
range of temperatures (4–50 K). Notably, all of the MCD sig-
nals are temperature-dependent, indicating that they originate
from a paramagnetic metal. MCD signals at the most intense
feature (448 nm) weremonitored over a range ofmagnetic field
intensities at several temperatures (2.5–25 K). The resulting
magnetic saturation curves at the different temperatures over-
lap each other (supplemental Fig. S2), indicating that the spin
state of the iron is S  1⁄2. This result implies that the heme in
DGCR8 contains low-spin Fe(III), with only one unpaired
electron.
The EPR spectrum of frog DGCR8 HBD-His6 further sup-
ports the conclusion that the heme iron is low-spin Fe(III).
When the spectrum was scanned from 0–10,000 G, the only
signal observedwas a narrow rhombic signal centered at2900
G (data not shown). A narrow scan (2000–4000 G) around this
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FIGURE 4. The hyperporphyrin spectrum of DGCR8 likely results from
double-cysteine ligation to ferric heme. The electronic absorption spec-
trum of ferric heme-bound NC1 dimer (solid line) is strikingly similar to that of
the ferric chloroperoxidase complexed with ethyl-2-mercaptoacetate
(dashed line). The latter spectrum was reproduced from an earlier work (31).
FIGURE 5. Electronic absorption and MCD spectra of the ferric heme-
bound frog DGCR8 HBD-His6. The electronic absorption spectrum (top
panel) was taken at room temperature using the dimeric frog HBD-His6 at 12.2
M concentration in a buffer containing 50 mM EPPS (pH 8.0) and 400 mM
NaCl. As a control, an electronic absorption spectrum was also recorded at 4 K
and displayed no differences in peak positions and intensity (data not
shown). The MCD spectrum (bottom panel) was recorded using a protein sam-
ple at 24.5 M in 22.5 mM EPPS (pH 8.0), 180 mM NaCl, and 55% (v/v) glycerol.
FIGURE 6. EPR spectrum of the ferric heme-bound frog DGCR8 HBD-His6
protein. The frog HBD-His6 protein (153 M) was in 50 mM EPPS (pH 8.0) and
400 mM NaCl. The spectrum represents an average of 10 scans taken at 10 K,
with 9.383 GHz microwave frequency, 8.000 G modulation amplitude, 100
kHz modulation frequency, 60 dB receiver gain, 163.84 ms time constant, and
a power of 1.002 milliwatt. The asterisk represents a signal present in the
cavity.
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rhombic signal gave the three g values: gz  2.60, gy  2.27, and
gx  1.84 (Fig. 6). The presence of a single rhombic signal in the
g  2 region reveals that the iron in DGCR8 is clearly low spin
Fe(III). Analysis of the calculated crystal field parameters of
tetragonality (	/, degree of electronic donation at the iron
center) and rhombicity (V/	, degree of geometric distortion of
the iron center) places the frog Fe(III) HBD-His6 in the same
region as native ferric chloroperoxidase in the Blumberg-Pei-
sach “truth” diagrams (33), in closest proximity to Fe(III)
chloroperoxidase thiol adducts such as thioacetic acid and
-mercaptoethanol and the Fe(III) chloroperoxidase bis(hy-
droxymethyl)methyl phosphine adduct (32, 34) (supplemen-
tal Table S2 and Fig. S3). Although a number of thiol adducts
of ferric chloroperoxidase and ferric P450CAM display mul-
tiple overlapping, rhombic EPR signals, the frog Fe(III)
HBD-His6 only displays a single rhombic signal, suggesting a
well defined, homogenous environment about the DGCR8
heme.
The Sixth Axial Ligand of Heme in DGCR8 Is Not a
Methionine—Because both thiols andphosphines ligated to fer-
ric chloroperoxidase and P450 generate hyperporphyrin spec-
tra (5, 32), we considered the possibility that one of the ligands
coordinated to the heme in DGCR8 is the thioether of a methi-
onine side chain. We examined the spectroscopic properties of
the frog HBD-His6 labeled with SeMet, with the expectation
that if methionine were a ligand to the heme iron, its substitu-
tion with the selenium analog would be evident in the heme
spectra. A MALDI-TOF mass spectrum of the SeMet-labeled
HBD-His6 showed a single major peak with am/z value greater
than that of the unlabeled protein by 239, within experimental
error (  13) of the expected increase of 234 when all five
methionine residues in the frog HBD-His6 sequence are substi-
tuted with SeMet (Fig. 7A). This result indicated that nearly
complete substitution of methionine with SeMet was achieved.
Importantly, the electronic absorption spectrum of SeMet-la-
beled frog HBD-His6 shows no changes in peak positions rela-
tive to the native construct (Fig. 7B). In contrast, previous stud-
ies showed that substitution of amethionine ligand with SeMet
caused the Soret  and  peaks to red-shift on the range of 3–7
nm (35, 36). The signals in theMCD and EPR spectra of SeMet-
labeledHBD-His6were also unchanged from those of the native
Met-containing protein (Fig. 7, C and D). The large difference
in spin-orbit coupling between Se and S is expected to give rise
to significantly different spectral features; that the MCD and
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FIGURE 7. The sixth ligand to ferric heme in DGCR8 is not a methionine. A, mass spectra of native and SeMet-labeled frog DGCR8 HBD-His6 indicates nearly
complete substitution of Met by SeMet. The difference in their m/z peaks, 239, is consistent with all five methionine residues substituted with SeMet. B, the
normalized electronic absorption spectrum of the SeMet-substituted frog HBD-His6 is nearly identical to that of the native protein (Fig. 5, top panel). C, the normalized
MCD spectrum of the SeMet-substituted frog HBD-His6 is nearly identical to that of the native protein (Fig. 5, bottom panel). D, comparison of the EPR spectra of the
native and SeMet-labeled frog HBD-His6. The spectral parameters for the SeMet-labeled frog HBD-His6 were the same as those of the native listed in Fig. 6, except that
the ferric heme concentration of the sample was 142 M and the spectrum was acquired with a 9.384 GHz microwave frequency.
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EPR spectra of the two proteins are the same argues thatmethi-
onine is not the sixth ligand to the heme in DGCR8. Thus,
DGCR8 must use two endogenous cysteine residues to ligate
heme.
Cys-352 from both Subunits in a DGCR8 Dimer Serve as the
Axial Ligand of Heme—Which cysteine residues does DGCR8
use for ligating heme? There are seven cysteine residues in the
NC1 (human) sequence; however, only two of them, Cys-352
and Cys-430, are located in the HBD region. Available data
suggest that the HBD binds heme in the same way as NC1 (19)
and that Cys-430 is not required for associationwith heme (10).
Thus, Cys-352 is the only cysteine residue in human DGCR8
that can serve as a ligand for heme. Furthermore, heme binds to
dimeric DGCR8, suggesting a model in which the two Cys-352
from both subunits serve as the axial ligands of heme.
We directly tested this model using amercury titration strat-
egy. Mercury compounds bind thiol groups with high affinities
and thus can disrupt the interaction between cysteine ligands
and the heme cofactor. To simplify the interpretation, we first
mutated Cys-430 to serine in the context of human DGCR8
HBD-His6 (hHBDC430S) so that Cys-352 was the only cysteine
present in the sequence. Not surprisingly, themutant exhibited
an electronic absorption spectrum with peak positions and rel-
ative intensities indistinguishable from those of the wild-type
protein (Fig. 8). This result confirms experimentally that Cys-
352 is the only cysteine residue that can ligate heme. Titration
of the hHBDC430S dimer with MeHgAc led to a linear decrease
of the peaks at 366, 450, and 556 nm until 2.0 molar equivalents
(relative to hHBDC430S dimer) was reached. The peaks disap-
peared completely after addition of 2.5 molar equivalents of
MeHgAc (Fig. 8). Concomitantly, there appeared a broad elec-
tronic absorption peak centered at 385 nm resembling that of
free ferric heme (Fig. 8), suggesting that the heme was released
from hHBDC430S after both Cys-352 ligands dissociated from
the heme iron. Consistent with this interpretation, when 1.2
molar equivalents of apomyoglobinwere added to themercury-
treated hHBDC430S dimer, the Soret peak shifted to 409 nm,
characteristic of ferric myoglobin (metmyoglobin). Because
each methylmercury generally binds one cysteine in a protein,
these results indicate that both Cys-352 residues in the
hHBDC430S dimer are important for association with heme.
Heme Binds to DGCR8 Expressed in Eukaryotic Cells—We
have studied the DGCR8-heme interaction using overexpres-
sion inE. coli or biochemical reconstitution; however, the ques-
tion remains: does this family of proteins, found only in ani-
mals, bind heme in eukaryotic cells? Because overexpression of
DGCR8 in mammalian cells is subjected to multiple levels of
regulation (37) and appears to be cytotoxic, we addressed this
question by expressing NC1 with a N-terminal His6 tag (His6-
NC1) in Sf9 insect cells (Fig. 9). The purified His6-NC1 protein,
which appeared largely as a single band, displayed absorption
peaks at 366, 450, and 556 nm (Fig. 9A), identical to those of the
NC1-ferric heme complex expressed in bacteria. This His6-
NC1 protein sample was further analyzed using SEC (Fig. 9B).
The chromatogram showed that the insect cell-expressedHis6-
NC1 eluted at a volume expected for the NC1 dimer, and no
monomer peak was visible, suggesting that the His6-NC1
existed nearly exclusively as a dimer. SEC also allowed the small
amounts of protein and nucleic acid impurities to be removed
from His6-NC1. Based on the absorbance ratio A450/A280, the
heme occupancy of the insect cell-expressed His6-NC1 was
estimated to be 50%.We tested the His6-NC1 using reconsti-
tuted pri-miRNA processing assays. This assay revealed that
the activity of the Sf9-expressed His6-NC1 was comparable
with that of the heme-bound NC1 dimer expressed in bacteria
(Fig. 9C). Given these data, we conclude that active DGCR8
proteins expressed in eukaryotic cells can bind heme.
DISCUSSION
Here we present biochemical and spectroscopic characteris-
tics of the DGCR8-heme complex, revealing interactions dis-
tinct from those of other known cysteine-ligated hemoproteins.
The DGCR8-heme complex displays an absorption spectrum
with an intense peak near 450 nm in the absence of CO. Our
data reveal that the heme iron is in the ferric state and that
DGCR8 ligates to the heme iron using two endogenous cysteine
side chains (Fig. 10).
Our recent crystal structure of the N-terminal dimerization
subdomain of the human DGCR8 HBD revealed a symmetric
dimer with an extensive dimerization interface mediated
mostly by hydrophobic interactions (19). Although our struc-
ture does not contain heme, it shows that the two Cys-352 res-
idues in the dimer are within van derWaals contacting distance
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FIGURE 8. Cys-352 from both subunits in a DGCR8 dimer serve as the axial
ligands to ferric heme. Electronic absorption spectra of hHBDC430S (10 M)
titrated with MeHgAc. The MeHgAc was added at steps of 0.5 molar equiva-
lent of ferric heme-bound HBD dimer. The spectra of the starting point (0
molar equivalent of MeHgAc) and end point (2.5 molar equivalents) are
shown in solid traces and the intermediate steps in dotted lines. After the
MeHgAc titration, 1.2 molar equivalents of apomyoglobin (relative to the
HBD dimer) were added, and the electronic absorption spectrum was
immediately recorded (dashed line). The inset shows absorbance at 450 nm
over the course of the titration.
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of each other. A conformational change of the loop containing
Cys-352 likely occurs upon association of the protein with
heme and should be able to position the two Cys-352 side
chains on opposite sides of the heme plane for axial ligation.
Here we show that the DGCR8-heme complexes are remark-
ably stable (Fig. 2C). Proper positioning of the two Cys-352 side
chains within a robust dimer likely contributes to this stability.
This study establishes DGCR8 as the first example of a heme
protein with two endogenous cysteines, Cys-352 from both
subunits, as axial ligands. Our investigation revealed that Pro-
351 is important for the stability of the DGCR8-heme complex.
Pro-351 and Cys-352 together are similar to the heme regula-
torymotif, which contains a Cys-Pro sequence but in the oppo-
site order. Heme regulatory motifs directly bind heme and are
found in repeats in a range of heme-regulated proteins, such as
the yeast transcription activator HAP1 and the human -ami-
nolevulinic acid synthase, heme oxygenase-2, heme-regulated
eukaryotic initiation factor 2 kinase, and Rev-erb (38–42). It
is possible that in both motifs the proline helps to position the
cysteine side chain in an appropriate geometry for ligation and
for either catalytic or regulatory functions. However, unlike the
heme regulatory motifs, the Pro-351 and Cys-352 residues are
not sufficient for DGCR8 to associate with heme, because
dimerization and Trp-329 in the WW motif are also required
for heme binding.
Our previous (10) and current studies clearly demonstrated
that dimerization is required for association with heme. The
heme-free forms of NC1 expressed in E. coli are either mostly
monomeric (for the wild type and the C351Amutant) (10) or a
mixture of monomers and dimers (for P351A, this study). We
have never observed monomeric NC1 to bind heme and
dimerize in vitro, regardless of whether it is the wild type or the
P351A mutant, (Fig. 3D and data not shown). Furthermore, it
appears that themonomeric species ofNC1 is only generated in
E. coli and not in insect cells (Fig. 9B). A careful inspection of
the SDS-12% polyacrylamide gels of the bacteria-expressed
NC1 revealed that the monomer contained low-molecular-
weight protein species comigrating with the dye bromphenol
blue (supplemental Fig. S4, A and B). On a SDS-15% polyacryl-
amide gel, these protein species appeared as an approximately
10-kDa bandwith a smear underneath (supplemental Fig. S4C),
indicating that they are heterogeneous. Furthermore, our crys-
tal structure of the N-terminal sub-domain of human DGCR8
HBD shows an extensive dimerization interface that does not
appear to be easily disrupted in non-denaturing conditions.
Thus, the “monomeric” NC1 may partially, if not entirely, con-
sist of heterodimers in which one subunit has been non-specif-
ically cleaved in the central loop region (19) of its HBD, in the
E. coli cells or during purification, into a fragment that retains
the dimerization domain. It is possible that in human cells both
heme-free and heme-bound DGCR8 are dimers.
The current study reveals important features of the DGCR8-
heme interaction that will help us to understand its potential
physiological function in regulating miRNA maturation. We
have twoworkingmodels. In the first model, the DGCR8-heme
complex may serve as a sensor for cellular or environmental
signals (the heme-based sensor model) (43). In a heme-based
sensor, heme is stably bound to a protein partner, which is
consistent with the slow dissociation of heme from NC1
observed here (Fig. 2C). In the second, heme itself may serve as
350 400 450 500 550 600 650
0.00
0.01
0.02
0.03
0.04
0.05
450 nm
366 nm
556 nm
R
N
A
E. coli
NC1
10050
Insect 
His6-NC1
nMM
Size (nt)
150
100
90
80
30
40
50
60
70
20
50
Pri-miR-30a 
   (150 nt)
Pre-miR-30a 
     (63 nt)
3’ Product 
     (52 nt)
5’ Product 
    (35 nt)
M
6 8 10 12 14 16 18 20
0.0
2.5
5.0
7.5
10.0
280 nm
450 nm
100
80
40
50
60
Size
(kDa)
80
40
50
60
Size
(kDa)
M
100
12.1 mL*
FIGURE 9. DGCR8 binds heme in insect cells. A, electronic absorption spectrum of His6-NC1 (human) expressed in Sf9 cells using baculovirus. His6-NC1 was
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FIGURE 10. Schematic of how the DGCR8 HBD binds ferric heme.
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the ligand to activate miRNA processing (the heme sensing
model) (21). The slow dissociation of heme from NC1 argues
against a heme sensingmodel inwhich heme reversibly binds to
DGCR8 and regulates its activity. However, it is still possible
that heme may bind and activate DGCR8 while the signal is
turned off through protein degradation.
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